Opana (Oxymorphone) is a brand name semi-synthetic opioid medication manufactured by Endo Pharmaceuticals primarily for the treatment of moderate to severe pain. In addition to its usage for pain management, Opana is sometimes administered as an adjunct for the maintenance of preoperative anesthesia. The active ingredient within Opana known as “oxymorphone,” is produced from thebaine, a minor opiate alkaloid derived from opium poppy (Papaver somniferum).
Like morphine and other opioids, Opana functions via binding to mu opioid receptors (MORs) in the brain as a full agonist. This full agonism at the mu opioid receptor sites yields potent analgesic effects, thereby attenuating severe pain. Mu opioid receptor agonism is also associated with anxiolytic effects, euphoria (or improved mood), and physical relaxation. As a result of these effects, many individuals seek to attain opioids like Opana to attain a neurophysiological “high” rather than to treat a legitimate medical condition.
For this reason, Opana (and other opioids) are classified as “Schedule II” controlled-substances, indicating their high propensity for abuse, dependence, and misuse. A standard drug test implemented by employers is capable of detecting the ingestion of opioids like oxymorphone, resulting in anxiety among many Opana users that they may fail a drug test. Regardless of whether you’re concerned about a drug test or simply attempting to detox, you may want to know how long Opana stays in your system after your final dose.
How long does Opana stay in your system? (Oxymorphone)
Assuming you’ve stopped taking Opana to get the oxymorphone out of your system, you may notice the emergence of hellacious Opana withdrawal symptoms (especially if you were a long-term user). During your transition to sobriety, you may wonder how long it’ll take before you’re fully detoxified from Opana. To consider how long Opana stays in systemic circulation after your final dose, it is necessary to understand the elimination half-life of its active ingredient “oxymorphone hydrochloride.”
The half-life of oxymorphone hydrochloride within Opana is chiefly contingent upon whether it is administered in its respective “ER” (extended-release) or “IR” (immediate-release) format. If administered as Opana ER, the oxymorphone hydrochloride exhibits an elimination half-life within the range of 9 to 11 hours. If administered as Opana IR, the oxymorphone hydrochloride’s half-life is reportedly within the range of 7.3 and 9.4 hours.
Knowing the half-lives of respective Opana formulations, we can estimate that it’ll take between 2.06 and 2.52 days to eliminate the “ER” version and between 1.67 and 2.15 days to eliminate the “IR” version from systemic circulation. In other words, the oxymorphone should be completely out of your system within 3 days of discontinuation – regardless of whether you took Opana ER or Opana IR. It should also be noted that metabolites of oxymorphone (6-OH-oxymorphone and oxymorphone-3-glucuronide) do not exhibit longer half-lives than the parent drug (oxymorphone), and therefore should also be cleared within 3 days.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/15777102
- Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888551/
Variables that influence how long Opana stays in your system
There are many variables that may influence how long your body is likely to retain Opana (oxymorphone hydrochloride) and its metabolites within systemic circulation. Examples of such variables include: Opana format (ER vs. IR), attributes and health of the user, dosage ingested, and term of administration. Realize that it is these variables that influence whether you’re likely to clear Opana quicker or slower than average from systemic circulation.
Opana format (“ER” vs. “IR”)
Opana is manufactured in multiple formats including an “ER” (extended-release) and “IR” (immediate-release). Opana ER is more popular than the standard Opana IR formulation and provides a steady release of oxymorphone hydrochloride over a longer duration. Though most individuals using brand name “Opana” are taking the ER version, it is necessary to account for the slight differences in elimination half-lives between the ER and standard (IR) formats.
Opana ER: The extended-release version of Opana has a half-life ranging from 9 to 11 hours (for an average of 10). Each “ER” tablet is engineered to contain a INTAC® hydrophilic matrix comprised of high-molecular-weight polyethylene oxides to control drug release. The oxymorphone hydrochloride delivered from Opana ER reaches peak serum concentrations within 2 to 3 hours, and is fully eliminated from systemic circulation in around 2.29 days.
Opana IR: The standard immediate-release version of Opana exhibits a half-life ranging from 7.3 to 9.4 hours (for an average of 8.35 hours). The oxymorphone hydrochloride delivered from standard Opana peaks in the serum within 30 minutes of oral administration which is markedly faster than the ER’s peak. The standard Opana IR should be eliminated from systemic circulation in approximately 1.91 days.
With some basic calculations, we can estimate that the oxymorphone delivered from standard Opana (IR) will be eliminated from a user’s system approximately 9.12 hours faster than that delivered from Opana ER. The differences in the half-lives are primarily due to the engineering of the respective tablets. The ER tablet is designed to yield a longer duration of effect and altered delivery of oxymorphone hydrochloride, therefore it is no surprise that oxymorphone from Opana ER stays in the system longer than that from standard IR.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/15777102
- Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888551/
Multiple individuals could simultaneously ingest 20 mg of Opana ER, yet one individual would likely eliminate the drug quicker (at least slightly) than the other user. In this case, the difference in elimination half-life is unexplainable by dosage, Opana format, nor the time of administration (as it was simultaneous). For this reason, it is necessary to acknowledge that interindividual factors such as a person’s age, body mass, genetics, food intake, renal function, etc. – may determine Opana’s elimination half-life for a specific user.
Age: The age of an Opana user may determine how long the oxymorphone remains in systemic circulation upon discontinuation. Elderly individuals (over the age of 65) often exhibit poorer renal and hepatic function, which can both alter the pharmacokinetics of Opana, thereby increasing its elimination half-life. It is also necessary to consider that elderly individuals are more likely (than average) to be taking additional medications, have other health complications, and altered fat disposition, each of which may prolong elimination of Opana compared to younger adults.
Some research has demonstrated increases in plasma concentrations of oxymorphone by nearly 40% among elderly following administration of Opana ER. From this information it is logical to speculate that elimination half-life would be protracted. If you are a younger individual without major health problems, you should eliminate Opana from your system more efficiently than an elderly patient.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/17658959
Alcohol ingestion: Research has determined that co-ingestion of alcohol along with Opana can affect its bioavailability. Alcohol increases the peak plasma concentrations of Opana between 70% to 270% depending on the individual. It appears as though the strength of alcohol administered influences the plasma concentrations of Opana; the greater the potency of the alcohol, the higher the plasma concentrations of oxymorphone hydrochloride.
It should be noted that in certain outliers, alcohol actually decreased oxymorphone plasma concentrations. Medical literature advises strongly against concomitant ingestion of alcohol and Opana. However, should you have ingested alcohol along with your Opana dose, expect plasma concentrations to be greater, and possibly a protracted elimination half-life.
Body mass + Fat (%): A person’s body mass and fat percentage can influence how long Opana stays in their system. Individuals with a high percentage of body fat may exhibit increases in time to attain steady state concentrations of Opana due to altered disposition. However, with frequent dosing, it is likely that oxymorphone’s lipophilicity will facilitate accumulation within fat stores throughout the body.
Since obese individuals or those with a high percentage of body fat tend to have more fat stores for which oxymorphone may accumulate, it may take longer to eliminate upon lipophilic storage. Furthermore, research of obese and non-obese patients indicates that obese individuals experience variation in drug distribution, elimination, and clearance of drugs. It could therefore be hypothesized that Opana would remain in the system of a larger individual for a longer-than-average term upon discontinuation.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/19743886
Food intake: Multiple studies have examined the impact of food intake on the bioavailability of orally ingested Opana ER (at doses of 20 mg and 40 mg). Results noted that food intake prior to ingestion of Opana ER increased maximum serum concentrations compared to those taking the drug in a “fasted” state. Administration of a single 40 mg dosage of Opana ER to fasted individuals yielded peak plasma concentrations of 2.8 ng/ml within 60 minutes of ingestion.
Those that ate food prior to ingesting 40 mg Opana ER attained peak plasma concentrations of 4.25 ng/ml at 2 hours post-ingestion. Consumption of food immediately prior to ingestion of Opana ER may extend the time that it remains in systemic circulation. Therefore if you ate a large meal before taking Opana ER, it may take longer to eliminate from your plasma than had you taken it on an empty stomach.
- Source: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201655s004lbl.pdf
Hepatic function: It is understood that hepatic impairment can affect the bioavailability of Opana. Individuals with mild hepatic impairment exhibit an approximate 1.6-fold increase in bioavailability of Opana compared to those with normative hepatic function. Severe forms of hepatic impairment can increase its bioavailability by up to 12.2-fold.
Despite increased bioavailability, there isn’t clinically significant evidence to suggest that any degree of hepatic impairment increases the elimination half-life of Opana. That said, it is important to consider that individuals with severe forms of hepatic impairment may be at increased risk for longer elimination half-lives of Opana. Clearly hepatic function doesn’t have a major impact on elimination of Opana, but it may still have a minor influence.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/17658959
Metabolic rate: The basal metabolic rate (BMR) of your body is thought to affect drug metabolism. The higher your BMR, the more likely you’ll be to rapidly metabolize and eliminate Opana from systemic circulation. The lower your BMR, the slower the pace at which you’ll be expected to metabolize Opana and excrete it from your body. Though BMR is unlikely to have a major impact on elimination of Opana, it is likely to have some impact, even if it’s just a minor one.
- Source: https://books.google.com/books?id=az8uSDkB0mgC
Renal function: It is likely that an individual’s renal function may affect how long Opana stays in his/her system. A majority of an Opana dosage is excreted from the body via the kidneys after forming various metabolites. There is evidence that these metabolites are subject to accumulation in the kidneys among individuals with impaired renal function.
Renal metabolite accumulation often leads to reabsorption and recirculation of the drug throughout the body. Therefore it is likely that an individual with severe renal impairment would exhibit an increase (even if slight) in the elimination half-life of Opana ER. Elimination half-life is likely to increase in respect to the degree of impairment; the greater the impairment, the more accumulation of metabolites, and longer term of elimination.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/15920941
Dosage (5 mg to 40 mg)
Regardless of the Opana format that you administer (ER or IR), the dosage that you take can affect how long the drug stays in systemic circulation. Common sense would suggest that the lower the dosage of Opana you take, the quicker your body will eliminate the oxymorphone (and metabolites) from plasma circulation. Assuming you were to take Opana ER which exhibits a ~10 hour half-life, a dosage of 40 mg Opana ER would likely stay in your system for longer than a dosage of 10 mg Opana ER.
Based on the 10 hour half-life, the 40 mg ER dosage would’ve plummeted to 20 mg within the plasma, whereas the 10 mg dosage would’ve dropped to just 5 mg in the plasma. Low dose users have less oxymorphone in circulation in the first place, meaning plasma concentrations will be reduced to a considerably lower amount than high dose users. Furthermore, less metabolites form as a result of lower doses and renal excretion is more efficient because there are fewer metabolites to eliminate.
At higher doses, renal excretion may become less efficient as a result of increases in metabolites to eliminated. These metabolites may accumulate to a greater extent within renal pathways and fat stores throughout the bodies of high dose users, resulting in prolonged elimination. A major reason that an individual may be more likely to fail a drug test following Opana ingestion is that they took a high dose.
Though complete plasma elimination is likely to occur within 2.29 days for nearly all Opana ER users, greater levels of oxymorphone (and metabolites) will be apparent in the blood and urine of high-dose users. It is the greater levels of oxymorphone and metabolites for an extended duration that may lead to failure of a mandatory opioid test. Know that low dose users should eliminate Opana with greater efficiency and are less likely to fail an opioid test than high dose users.
Frequency/Term of administration
The frequency at which you administer Opana, along with the cumulative term of administration may affect how long it stays in your system. Someone that infrequently uses Opana is less likely to accumulate the drug within their fat stores and/or renal pathways, leading to faster elimination. Additionally, less frequent usage is associated with reduced propensity of dependence or physiologic tolerance, meaning infrequent users may take a lower dosage of Opana.
As was already mentioned, lower dose usage (especially infrequent) is likely to be excreted quicker than high dose usage. A frequent user of Opana may administer secondary and tertiary daily doses of the drug before the initial dosage has undergone metabolism. This means that a greater level of unmetabolized oxymorphone will be in systemic circulation.
Additionally, the total daily dosage is often greater amount those who administer Opana frequently for multiple reasons. Firstly, more frequent administration often leads to tolerance, requiring upward titrations in dosing. Secondly, the more frequently an individual administers Opana, the more likely they are to have ingested a higher daily dosage than a single-dose or infrequent user – leading to less efficient, protracted elimination.
It should also be noted that the duration of administration (long-term vs. short-term) may also determine how long Opana stays in your system. Long-term users are more likely to have become dependent upon the drug’s effects, are taking higher daily doses as a result, and the neurophysiologic effects resulting from dependence may prolong oxymorphone’s elimination. In other words, the physiology expects to receive the drug often, but its capacity for efficient elimination may be reduced.
Steady state concentrations are known to be attained within 3 days of dosing in accordance with medical guidelines. Individuals that dose improperly and/or have been taking the drug for less than 3 days should eliminate it from their systems in a shorter duration than someone who’s attained steady state levels. In summary, expect Opana to remain in your system for a longer duration if you were a long-term, frequent user.
Opana: Absorption, Metabolism, Excretion (Details)
Following oral administration of Opana, its pharmacologically active ingredient “oxymorphone” is well absorbed by the gastrointestinal (GI) tract. It undergoes first-pass hepatic metabolism, hence the reason as to why it has such a low bioavailability of just 10%. It should be noted that food intake and alcohol are known to affect the bioavailability and maximum plasma concentrations of oxymorphone.
Food intake prior to ingestion increases maximum plasma concentrations by up to 50%, whereas concomitantly administered alcohol increases them by over 70%. Hepatic metabolism of oxymorphone is extensive as upwards of 98% of the oxymorphone forms metabolites; leaving just 2% unchanged. A majority of hepatic oxymorphone metabolism involves its conjugation with glucuronic acid, forming two notable metabolites: oxymorphone-3-glucuronide (O3G) and 6-OH-oxymorphone.
The predominant metabolite of oxymorphone is oxymorphone-3-glucuornide, whereas 6-OH-oxymorphone is formed in lesser amounts. Although 6-OH-oxymorphone metabolites are suspected to be pharmacologically active, it remains unknown as to whether oxymorphone-3-glucuronide is pharmacologically active. Upon attainment of steady state concentrations, plasma levels of 6-OH-oxymorphone are nearly equal to those of oxymorphone, whereas oxymorphone-3-glucuronide levels are ~90-fold greater.
After its metabolism, oxymorphone is distributed at a volume of approximately 3 liters per kilogram (akin to morphine) and is 10% bound to plasma proteins. Upon distribution, the high lipophilicity of oxymorphone allows it to efficiently travel throughout the CNS (central nervous system), binding to mu-opioid receptors (MORs) for pain relief. Plasma concentrations of oxymorphone peak in approximately 30 minutes when administered in standard (Opana IR) formats and between 2 and 3 hours when administered as extended-release (Opana ER) formats.
Steady state concentrations of oxymorphone are attained within approximately 72 hours (3 days) of consistent administration. The half-life of Opana varies based on whether it is administered in standard or extended-release format. Half-life for the standard format is ~8.35 hours, whereas its reported half-life for the extended-release version is ~10 hours.
This implies that Opana should be out of systemic circulation within 3 days of discontinuation. Due to the fact that it is extensively metabolized via conjugation with glucuronic acid in the liver, less than 1% of the dosage is excreted as unchanged oxymorphone within the urine. Up to 38% of a dose is excreted via urine as oxymorphone-3-glucuronide metabolites, and less than 1% is excreted as 6-OH-oxymorphone.
A small percentage of the drug is also excreted from the body via feces. A majority of the drug will have been fully excreted as metabolites within 5 days. However, for complete excretion of metabolites (primarily oxymorphone-3-glucuronide) via urine and/or feces, it could take up to a week in a high-dose, chronic user. That said, a majority of users shouldn’t need to worry about failing a drug test after 5 days post-ingestion.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/19209260
- Source: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201655s004lbl.pdf
Types of Opana Drug Tests (Oxymorphone)
Since oxymorphone is considered a narcotic semi-synthetic opioid, its metabolites are likely to be detected on a standard drug test such as the SAMHSA-5. Individuals that ingest Opana within a week of a drug test may risk testing positive for opioids. Examples of some types of drug tests capable of detecting oxymorphone metabolites include: urine tests, blood tests, hair tests, and saliva tests.
Urine tests: A urine test involves collecting a fresh urine sample from a prospective oxymorphone user and assessing it for the presence of oxymorphone metabolites such as oxymorphone-3-glucuronides (O3G) and 6-OH-oxymorphone. Due to the fact that oxymorphone-3-glucuronides are most abundant within urinary excretion of an Opana user, it is O3G levels that would most likely be analyzed via techniques such as high performance liquid chromatography (HPLC).
Because oxymorphone is subject to extensive hepatic metabolism, less than 2% of an Opana dose is excreted as unchanged oxymorphone within the urine. Peak concentrations of oxymorphone and its metabolites are thought to appear within urine in less than 24 hours of dosing, but may remain for up to 48 hours in some users. Detectability of these metabolites in urinary excretion may be possible for up to 5 days after ingestion.
However, duration of urinary metabolite detectability will be largely contingent upon dosage and whether the individual tested was a chronic or acute user. It is unlikely that oxymorphone metabolites from Opana ER or standard Opana would remain detectable for longer than 7 days post-ingestion.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/7536861
Blood tests: It is also possible to detect Opana ingestion via blood tests. A blood test is likely to provide a shorter window of detection than a urine test, simply because oxymorphone is eliminated from the plasma faster than its metabolites are excreted via the urine. That said, a blood test can provide highly accurate information regarding precisely how much Opana was likely to have been ingested during intoxication.
A blood test will determine oxymorphone levels most accurately if administered approximately 30 minutes after ingestion of Opana IR, and between 2 to 3 hours after ingestion of Opana ER. Opana ER will remain detectable for a longer duration than Opana IR on a blood test simply because it has a longer duration of effect. Since concentrations of oxymorphone-3-glucuronide are approximately 90-fold that of the parent drug (oxymorphone), it is O3G levels that will be measured on a blood test.
If the levels are above a certain threshold, an individual will test positive for opioid ingestion. That being said, blood tests are highly invasive and are less convenient than urine testing. For these reasons, they are typically reserved to either confirm results of a urinalysis, for scientific research, and/or for hospitalized patients.
Hair tests: It is unclear as to the degree of oxymorphone detectability on a hair analysis following administration of Opana. Hair tests are advantageous over many other drug testing methods for the fact that they provide a long window of detection (upwards of 1 month) after ingestion. Furthermore, hair testing is considered non-invasive and often yields accurate information regarding frequency and term of opioid administration.
Individuals subject to hair testing following Opana ingestion may have accumulated oxymorphone metabolites such as oxymorphone-3-glucuronide within hair follicles. If the drug was ingested recently, these metabolites are likely to appear within proximal segments of collected follicles. If there was a considerable gap between hair follicle analysis and Opana ingestion, metabolites may be more likely to appear within the medial and/or distal regions.
Hair testing is not typically utilized by employers to detect drug ingestion among employees, but may be requested by medical professionals to gauge drug abuse over an extended duration. It is relatively easy to distinguish individuals that have abused opioids from those ingesting standard doses based on their respective hair samples.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/17898660
Saliva tests: The detection rates of oxymorphone in oral fluid (along with its metabolites) are poorer than in urine. Furthermore, the short elimination half-life of Opana indicates that it is likely to be eliminated from plasma within just 2.29 days of ER (extended-release) dosing and under 24 hours of IR (immediate-release) dosing. Therefore detection of Opana metabolites such as oxymorphone-3-glucuronide in oral fluid is likely restricted to the initial 24 hours after ingestion.
Oxymorphone and metabolites should be most readily detectable in oral fluid as plasma concentrations peak; this occurs between 30 minutes and 3 hours (depending on whether taking Opana ER or the standard version). An Opana user is unlikely to fail a salivary screening if the oral fluid is collected 2 days after ingestion. Due to the short window of detection and inaccuracies associated with saliva testing, other modalities of Opana screening are preferred.
- Source: http://www.ncbi.nlm.nih.gov/pubmed/22337775
Who may be tested for Opana?
An array of individuals may be screened for opioids, and thus may fail a drug test after ingestion of Opana. Examples of individuals subject to Opana drug testing include: athletes, criminals, rehab patients, employees, military members, and possibly students. Realize that should any of these individuals fail an opioid screening, they may be subject to harsh penalization.
- Athletes: High-level collegiate, professional, and Olympic athletes are commonly tested for illicit and prescription drugs. Should any athletes fail a drug test as a result of ingesting Opana, they may be banned and/or withheld from competition. Unless the Opana was administered with medical approval and supervision, ramifications may be severe.
- Criminals: A criminal that is suspected by a law enforcement agent to have ingested an opioidergic drug may be tested for Opana. If the drug was ingested on an illicit basis and/or during a crime, a criminal may be subject to additional jail time, fines, and legal penalties.
- Drug rehab patients: Individuals in rehabilitation (especially for opioids) may be frequently screened for prescription drugs like Opana. If a patient in rehab is caught with oxymorphone metabolites in his/her system, rehabilitation professionals may recommend and/or require a longer stay at the facility.
- Employees: The fact that Opana acts as a CNS depressant is indicative of the fact that it can impair concentration, coordination, and vigilance. The onslaught of effects associated with opioidergic CNS depression can impair job performance, increase risk of serious injuries or fatalities, and may increase the likelihood of damaged equipment. For this reason, any employee caught with opioids in his/her system may be fired.
- Military personnel: Military members are often tested for opioids such as Opana. In the military, troops are required to maintain optimal levels of alertness while working with heavy machinery, communicating with other troops, and learning new skills. Opana ingestion may compromise the performance of a military member, ultimately leading to unwanted outcomes in battle. Should a troop get caught with Opana in his/her system, he/she may be delisted.
Tips to clear Opana from your system
There aren’t really any major tricks that can expedite the clearance of Opana from systemic circulation other than completely stopping. The sooner a person stops taking Opana, the quicker they can expect the drug (and its metabolites) to get eliminated. Below are some methods that may have a slight effect in expediting the elimination of oxymorphone. Should you consider implementing any of these suggestions, verify safety and alleged efficacy with a medical professional.
- Calcium-D-Glucarate: This supplement is known to function as a beta-glucuronidase inhibitor, essentially clearing out accumulated molecules within renal detoxification pathways. Since 38% of Opana’s chief metabolite oxymorphone-3-glucuronide is excreted via the kidneys, this supplement could be beneficial. Think of calcium-d-glucarate as giving your kidneys an added boost in regards to excretion speed and efficiency.
- Activated charcoal: If you took a large dose of Opana, immediate administration of activated charcoal could be helpful for clearing the drug quickly from systemic circulation. When administered within 20 minutes of Opana ingestion, activated charcoal binds to the drug and prevents its full absorption. This reduces the amount of oxymorphone that makes its way into your system. It could even be helpful to administer after ingestion for detoxification purposes; charcoal also binds to endotoxins.
- Hydration: Maintaining adequate hydration is known to increase urinary flow rate, which in turn can sometimes boost the efficiency of renal drug excretion. If you are dehydrated, your urinary flow rate is likely compromised and you may not be eliminating Opana metabolites as quickly as possible. To optimize efficiency of renal excretion, you may want to ensure that you’re drinking enough water.
- Exercise: Getting plenty of exercise may be helpful for long-term frequent Opana users simply because the metabolites may have accumulated within fat stores. If you are overweight and/or have a high percentage of body fat, exercise may help eliminate some of the fat stores that are harboring metabolites. This may essentially bolster the rate at which they are excreted from lingering within the system.
How long has Opana stayed in your system after stopping?
If you recently discontinued Opana, share a comment mentioning how long you think it stayed in your system. If you were subject to an opioid drug test and feared that Opana was detectable, mention whether you passed (e.g. tested negative) or failed (e.g. tested positive) the test. Discuss the type of drug test that was administered, the amount of time that had elapsed between your final Opana dose and your screening, as well as whether you were a chronic and/or high-dose user.
Realize that regardless of whether you were using standard Opana (IR) or Opana ER, the drug should be fully out of your system within 3 days of your last dose. Only in rare cases among high dose users would the drug possibly linger in the plasma for a longer term. Additionally, a bulk of Opana metabolites should be eliminated within urinary excretions up to 5 days post-discontinuation. The oxymorphone metabolites are unlikely to remain detectable after a full week of cessation.